Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 07h30 HE
|
Inozyme Pharma Inc.
BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...
Inozyme Pharma Reports Second Quarter 2022 Financial Results and Provides Business Updates
15 août 2022 07h30 HE
|
Inozyme Pharma Inc.
- Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency – - Appointed Kurt Gunter, M.D. as senior...
Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures
26 juil. 2022 07h30 HE
|
Inozyme Pharma Inc.
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal...
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)
19 juil. 2022 16h30 HE
|
Inozyme Pharma Inc.
- Rapid and significant increase in plasma pyrophosphate (PPi) levels observed in all three subjects in lowest dose cohort (0.2 mg/kg) – - INZ-701 was generally well-tolerated and exhibited a...
Inozyme Pharma Announces Partnership with Rady Children’s Institute for Genomic Medicine to Advance Newborn Screening for Genetic Diseases
16 juin 2022 07h30 HE
|
Inozyme Pharma Inc.
BOSTON, June 16, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal...
Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer
07 juin 2022 07h30 HE
|
Inozyme Pharma Inc.
BOSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal...
Inozyme Pharma to Present at the 2022 Jefferies Healthcare Conference
01 juin 2022 07h30 HE
|
Inozyme Pharma Inc.
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal...
Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights
10 mai 2022 07h30 HE
|
Inozyme Pharma Inc.
– Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency – – Preliminary biomarker and safety data from ongoing Phase...
Inozyme Pharma to Present at Upcoming Investor Conferences
03 mai 2022 07h30 HE
|
Inozyme Pharma Inc.
BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...
Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market
14 avr. 2022 08h16 HE
|
Inozyme Pharma Inc.
BOSTON, April 14, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal...